Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.

Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece.

Mavroeidis L, Metaxa-Mariatou V, Papoudou-Bai A, Lampraki AM, Kostadima L, Tsinokou I, Zarkavelis G, Papadaki A, Petrakis D, Gκoura S, Kampletsas E, Nasioulas G, Batistatou A, Pentheroudakis G.

ESMO Open. 2018 Apr 6;3(3):e000335. doi: 10.1136/esmoopen-2018-000335. eCollection 2018.

2.

Management of rectal gastrointestinal stromal tumor.

Kameyama H, Kanda T, Tajima Y, Shimada Y, Ichikawa H, Hanyu T, Ishikawa T, Wakai T.

Transl Gastroenterol Hepatol. 2018 Feb 1;3:8. doi: 10.21037/tgh.2018.01.08. eCollection 2018. Review.

3.

Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.

Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle IF, Castellani G, Remondini D, Fiorentino M, von Mehren M, Brandi G, Biasco G, Heinrich MC, Pantaleo MA.

Int J Mol Sci. 2018 Mar 4;19(3). pii: E732. doi: 10.3390/ijms19030732.

4.

Mechanisms of receptor tyrosine kinase activation in cancer.

Du Z, Lovly CM.

Mol Cancer. 2018 Feb 19;17(1):58. doi: 10.1186/s12943-018-0782-4. Review.

5.

Neoadjuvant therapy for gastrointestinal stromal tumor.

Ishikawa T, Kanda T, Kameyama H, Wakai T.

Transl Gastroenterol Hepatol. 2018 Jan 10;3:3. doi: 10.21037/tgh.2018.01.01. eCollection 2018. Review.

6.

Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs).

Yu K, Liu X, Jiang Z, Hu C, Zou F, Chen C, Ge J, Wu J, Liu X, Wang A, Wang W, Wang W, Qi Z, Wang B, Wang L, Yan H, Wang J, Ren T, Tang J, Liu Q, Liu J.

Oncotarget. 2017 Nov 15;8(67):111110-111118. doi: 10.18632/oncotarget.22624. eCollection 2017 Dec 19.

7.

Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease.

Platoff RM, Morano WF, Marconcini L, DeLeo N, Mapow BL, Styler M, Bowne WB.

Case Rep Oncol Med. 2017;2017:8349090. doi: 10.1155/2017/8349090. Epub 2017 Nov 30.

8.

Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature.

Boonstra PA, Gietema JA, Suurmeijer AJH, Groves MR, de Assis Batista F, Schuuring E, Reyners AKL.

Oncotarget. 2017 Nov 26;8(65):109836-109847. doi: 10.18632/oncotarget.22663. eCollection 2017 Dec 12.

9.

Management of liver metastases from gastrointestinal stromal tumors: where do we stand?

Machairas N, Prodromidou A, Molmenti E, Kostakis ID, Sotiropoulos GC.

J Gastrointest Oncol. 2017 Dec;8(6):1100-1108. doi: 10.21037/jgo.2017.08.08. Review.

10.

Characterization of malignant gastrointestinal stromal tumors-a single center experience.

Mandrioli M, Mastrangelo L, Masetti M, Zanini N, Lega S, Nannini M, Gruppioni E, Altimari A, Dei Tos AP, Fabbri C, Jovine E.

J Gastrointest Oncol. 2017 Dec;8(6):1037-1045. doi: 10.21037/jgo.2017.10.09.

11.

Two staging systems for gastrointestinal stromal tumors in the stomach: which is better?

Park CH, Kim GH, Lee BE, Song GA, Park DY, Choi KU, Kim DH, Jeon TY.

BMC Gastroenterol. 2017 Dec 6;17(1):141. doi: 10.1186/s12876-017-0705-7.

12.

Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study.

Zhao R, Wang Y, Huang Y, Cui Y, Xia L, Chen Y, Zhuang W, Zhou Y, Wu X.

Sci Rep. 2017 Dec 4;7(1):16834. doi: 10.1038/s41598-017-17266-5.

13.

Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.

Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, Zhang L, Li B, Fan LQ, Zhao Q, Ma ZX, Zhao XF, Zhang ZD, Liu Y, Tan BB, Wang D, Wang LL, Hao YJ, Jia N.

Medicine (Baltimore). 2017 Nov;96(46):e8240. doi: 10.1097/MD.0000000000008240.

14.

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.

Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, Lv Z, Wang Y, Chen Z, He J.

World J Surg Oncol. 2017 Nov 6;15(1):197. doi: 10.1186/s12957-017-1251-z.

15.

Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report.

Engin G, Eraslan S, Kayserili H, Kapran Y, Akman H, Akyuz A, Aykan NF.

World J Radiol. 2017 Sep 28;9(9):365-370. doi: 10.4329/wjr.v9.i9.365.

16.

Laparoscopic resection of gastrointestinal stromal tumors: Does laparoscopic surgery provide an adequate oncologic resection?

Kim JJ, Lim JY, Nguyen SQ.

World J Gastrointest Endosc. 2017 Sep 16;9(9):448-455. doi: 10.4253/wjge.v9.i9.448. Review.

17.

Metastatic gastrointestinal stromal tumor: A regional cancer center experience of 44 cases.

Suresh Babu MC, Chaudhuri T, Babu KG, Lakshmaiah KC, Lokanatha D, Jacob LA, Rudresha AH, Lokesh KN, Rajeev LK.

South Asian J Cancer. 2017 Jul-Sep;6(3):118-121. doi: 10.4103/sajc.sajc_290_16.

18.

KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.

Neiswender JV, Kortum RL, Bourque C, Kasheta M, Zon LI, Morrison DK, Ceol CJ.

Cancer Res. 2017 Nov 1;77(21):5820-5830. doi: 10.1158/0008-5472.CAN-17-0473. Epub 2017 Sep 25.

PMID:
28947418
19.

The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste-Reply.

Ikoma N, Araujo D, Roland CL.

JAMA Oncol. 2017 Dec 1;3(12):1740. doi: 10.1001/jamaoncol.2017.2503. No abstract available.

20.

Current research and treatment for gastrointestinal stromal tumors.

Lim KT, Tan KY.

World J Gastroenterol. 2017 Jul 21;23(27):4856-4866. doi: 10.3748/wjg.v23.i27.4856.

Supplemental Content

Support Center